Cargando…

Medication use during pregnancy and birth defects in Hunan province, China, during 2016–2019: A cross-sectional study

Safety of drug use during pregnancy attracts attentions from clinicians, pregnant woman, and even the total society. However, the studies about medication use during pregnancy and the followed birth defects (BDs) are rare in Chinese. To study condition about medication use during pregnancy and the f...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Wei, Xie, Shuting, Liang, Changbiao, Xie, Donghua, Fang, Junqun, Ouyang, Bo, Sun, Li, Wang, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542665/
https://www.ncbi.nlm.nih.gov/pubmed/36221426
http://dx.doi.org/10.1097/MD.0000000000030907
_version_ 1784804201017114624
author Zou, Wei
Xie, Shuting
Liang, Changbiao
Xie, Donghua
Fang, Junqun
Ouyang, Bo
Sun, Li
Wang, Hua
author_facet Zou, Wei
Xie, Shuting
Liang, Changbiao
Xie, Donghua
Fang, Junqun
Ouyang, Bo
Sun, Li
Wang, Hua
author_sort Zou, Wei
collection PubMed
description Safety of drug use during pregnancy attracts attentions from clinicians, pregnant woman, and even the total society. However, the studies about medication use during pregnancy and the followed birth defects (BDs) are rare in Chinese. To study condition about medication use during pregnancy and the followed BDs in Hunan province of China, here a cross-sectional study was carried out. All women using medication during pregnancy and delivering fetuses with BDs in Hunan province, China, during 2016 to 2019 were employed in this study. The descriptive analysis was carried out with Excel 2010, and the data analyses were performed by using Chi-Squared test in SPSS 16.0. After filtering, a total of 752 cases were included. In these fetuses, the males are more than females (P < .05). The severe BDs, leading to death or uncorrectable lifelong deformity, were observed for 346 times, and the other (minor) BDs were observed for 593 times. The most used drugs, categorized into pregnancy C, D, or X degrees by food and drug administration (FDA) or pharmaceutical manufacturers, mainly included anti-hyperthyroidism drugs, anti-epilepsy drugs, preventing miscarriage drugs, etc. This population-based data highlight the potential high risks for BDs from the aspect of drug use during pregnancy in Hunan province of China, and drugs with more safety, less kinds, and lower doses should be the better choice for pregnant women.
format Online
Article
Text
id pubmed-9542665
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-95426652022-10-11 Medication use during pregnancy and birth defects in Hunan province, China, during 2016–2019: A cross-sectional study Zou, Wei Xie, Shuting Liang, Changbiao Xie, Donghua Fang, Junqun Ouyang, Bo Sun, Li Wang, Hua Medicine (Baltimore) 4200 Safety of drug use during pregnancy attracts attentions from clinicians, pregnant woman, and even the total society. However, the studies about medication use during pregnancy and the followed birth defects (BDs) are rare in Chinese. To study condition about medication use during pregnancy and the followed BDs in Hunan province of China, here a cross-sectional study was carried out. All women using medication during pregnancy and delivering fetuses with BDs in Hunan province, China, during 2016 to 2019 were employed in this study. The descriptive analysis was carried out with Excel 2010, and the data analyses were performed by using Chi-Squared test in SPSS 16.0. After filtering, a total of 752 cases were included. In these fetuses, the males are more than females (P < .05). The severe BDs, leading to death or uncorrectable lifelong deformity, were observed for 346 times, and the other (minor) BDs were observed for 593 times. The most used drugs, categorized into pregnancy C, D, or X degrees by food and drug administration (FDA) or pharmaceutical manufacturers, mainly included anti-hyperthyroidism drugs, anti-epilepsy drugs, preventing miscarriage drugs, etc. This population-based data highlight the potential high risks for BDs from the aspect of drug use during pregnancy in Hunan province of China, and drugs with more safety, less kinds, and lower doses should be the better choice for pregnant women. Lippincott Williams & Wilkins 2022-10-07 /pmc/articles/PMC9542665/ /pubmed/36221426 http://dx.doi.org/10.1097/MD.0000000000030907 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 4200
Zou, Wei
Xie, Shuting
Liang, Changbiao
Xie, Donghua
Fang, Junqun
Ouyang, Bo
Sun, Li
Wang, Hua
Medication use during pregnancy and birth defects in Hunan province, China, during 2016–2019: A cross-sectional study
title Medication use during pregnancy and birth defects in Hunan province, China, during 2016–2019: A cross-sectional study
title_full Medication use during pregnancy and birth defects in Hunan province, China, during 2016–2019: A cross-sectional study
title_fullStr Medication use during pregnancy and birth defects in Hunan province, China, during 2016–2019: A cross-sectional study
title_full_unstemmed Medication use during pregnancy and birth defects in Hunan province, China, during 2016–2019: A cross-sectional study
title_short Medication use during pregnancy and birth defects in Hunan province, China, during 2016–2019: A cross-sectional study
title_sort medication use during pregnancy and birth defects in hunan province, china, during 2016–2019: a cross-sectional study
topic 4200
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542665/
https://www.ncbi.nlm.nih.gov/pubmed/36221426
http://dx.doi.org/10.1097/MD.0000000000030907
work_keys_str_mv AT zouwei medicationuseduringpregnancyandbirthdefectsinhunanprovincechinaduring20162019acrosssectionalstudy
AT xieshuting medicationuseduringpregnancyandbirthdefectsinhunanprovincechinaduring20162019acrosssectionalstudy
AT liangchangbiao medicationuseduringpregnancyandbirthdefectsinhunanprovincechinaduring20162019acrosssectionalstudy
AT xiedonghua medicationuseduringpregnancyandbirthdefectsinhunanprovincechinaduring20162019acrosssectionalstudy
AT fangjunqun medicationuseduringpregnancyandbirthdefectsinhunanprovincechinaduring20162019acrosssectionalstudy
AT ouyangbo medicationuseduringpregnancyandbirthdefectsinhunanprovincechinaduring20162019acrosssectionalstudy
AT sunli medicationuseduringpregnancyandbirthdefectsinhunanprovincechinaduring20162019acrosssectionalstudy
AT wanghua medicationuseduringpregnancyandbirthdefectsinhunanprovincechinaduring20162019acrosssectionalstudy